At a glance
- Originator Aventis
- Class Antimigraines
- Mechanism of Action Serotonin 1D receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 15 Sep 2004 Added "Aventis has since merged with Sanofi-Synthelabo to form Sanofi-Aventis"
- 17 Nov 2003 Discontinued - Preclinical for Migraine in USA (unspecified route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma